155 related articles for article (PubMed ID: 2959359)
1. Phase I study and pharmacokinetics of menogaril (NSC 269148) in patients with hepatic dysfunction.
Egorin MJ; Conley BA; Forrest A; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1987 Nov; 47(22):6104-10. PubMed ID: 2959359
[TBL] [Abstract][Full Text] [Related]
2. Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
Egorin MJ; Van Echo DA; Whitacre MY; Forrest A; Sigman LM; Engisch KL; Aisner J
Cancer Res; 1986 Mar; 46(3):1513-20. PubMed ID: 2935249
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of menogaril administered as an intermittent daily infusion for 5 days.
Sigman LM; Van Echo DA; Egorin MJ; Whitacre MY; Aisner J
Cancer Treat Rep; 1986 Jun; 70(6):721-5. PubMed ID: 2942244
[TBL] [Abstract][Full Text] [Related]
4. Phase I clinical investigation of 7-con-O-methylnogaril, a new anthracycline antibiotic.
Dorr FA; Von Hoff DD; Kuhn JG; Schwartz R; Kisner DL
Cancer Res; 1986 May; 46(5):2562-5. PubMed ID: 2938729
[TBL] [Abstract][Full Text] [Related]
5. Phase I and pharmacokinetic study of menogaril administered as a 72-hour continuous i.v. infusion.
Long HJ; Powis G; Schutt AJ; Moertel CG
Cancer Treat Rep; 1987 Jun; 71(6):593-8. PubMed ID: 2953414
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
[TBL] [Abstract][Full Text] [Related]
7. A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors.
Dees EC; Whitfield LR; Grove WR; Rummel S; Grochow LB; Donehower RC
Clin Cancer Res; 2000 Oct; 6(10):3885-94. PubMed ID: 11051234
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of menogaril in patients with advanced cancer.
Brown TD; Donehower RC; Grochow LB; Rice AP; Ettinger DS
J Clin Oncol; 1987 Jan; 5(1):92-9. PubMed ID: 2949065
[TBL] [Abstract][Full Text] [Related]
9. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
10. Phase I trial using adaptive control dosing of hexamethylene bisacetamide (NSC 95580).
Conley BA; Forrest A; Egorin MJ; Zuhowski EG; Sinibaldi V; Van Echo DA
Cancer Res; 1989 Jun; 49(12):3436-40. PubMed ID: 2720696
[TBL] [Abstract][Full Text] [Related]
11. Phase I clinical and pharmacokinetic study of hexamethylene bisacetamide (NSC 95580) administered as a five-day continuous infusion.
Egorin MJ; Sigman LM; Van Echo DA; Forrest A; Whitacre MY; Aisner J
Cancer Res; 1987 Jan; 47(2):617-23. PubMed ID: 3791246
[TBL] [Abstract][Full Text] [Related]
12. Metabolism and disposition of menogaril (NSC 269148) in the rabbit.
Dodion P; Egorin MJ; Engisch KL; Bachur NR
Cancer Res; 1985 Nov; 45(11 Pt 1):5352-7. PubMed ID: 2932217
[TBL] [Abstract][Full Text] [Related]
13. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
14. Feasibility study and pharmacokinetics of low-dose paclitaxel in cancer patients with severe hepatic dysfunction.
Briasoulis E; Karavasilis V; Tzamakou E; Piperidou C; Soulti K; Pavlidis N
Anticancer Drugs; 2006 Nov; 17(10):1219-22. PubMed ID: 17075322
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic trial of oral menogaril administered on three consecutive days.
Dodion P; de Valeriola D; Crespeigne N; Peeters B; Wery F; van Berchem C; Piccart M; Tueni E; Joggi J; Kenis Y
Eur J Cancer Clin Oncol; 1988 Jun; 24(6):1019-26. PubMed ID: 2970391
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of menogaril in renal cell carcinoma. A Southwest Oncology Group phase II study (8504).
Stephens RL; Goodman P; Crawford ED; Spicer CF; Lowe BA; Ahmann FR; Chapman R; Natale RB
Invest New Drugs; 1990; 8 Suppl 1():S69-71. PubMed ID: 2143177
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and dosage reduction of cis-diammine(1,1-cyclobutanedicarboxylato)platinum in patients with impaired renal function.
Egorin MJ; Van Echo DA; Tipping SJ; Olman EA; Whitacre MY; Thompson BW; Aisner J
Cancer Res; 1984 Nov; 44(11):5432-8. PubMed ID: 6386150
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456).
Vogelzang NJ; Mick R; Janisch L; Berezin F; Schilsky RL; Ratain MJ
Cancer Res; 1994 Jan; 54(1):114-9. PubMed ID: 8261430
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of oxaliplatin in patients with severe hepatic dysfunction.
Baur M; Drescher A; Gneist M; Dittrich C; Jaehde U
Cancer Chemother Pharmacol; 2008 Jan; 61(1):97-104. PubMed ID: 17396265
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of 4,4'-Thiobis(6- t -butyl- m -cresol) (CAS No. 96-69-5) in F344/N Rats and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1994 Dec; 435():1-288. PubMed ID: 12595928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
